Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
41128349 (PubMed )
Supplement: CAS-117-156-s003.xlsx › Sheet1
A neomorphic protein interface catalyzes covalent inhibition of RASG12D aspartic acid in tumors.
Weller C et al.
Science (new York, N.y.), 2025
40705880 (PubMed )
Supplement: science.ads0239_data_s1_to_s6.zip › science.ads0239_data_s4.xlsx › Sheet1
Hematologic Malignancy Frequency, Phenotypes, and Outcomes in Li-Fraumeni Syndrome.
Vagher J et al.
Jco Precision Oncology, 2025
40540701 (PubMed )
Supplement: DS2_PO-24-00860.xlsx › Supp_Table_2
Comparison of actionable alterations in cancers with kinase fusion, mutation, and copy number alteration.
Suzuki S et al.
Plos One, 2025
A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency.
Kohsaka S et al.
Npj Precision Oncology, 2024
38789724 (PubMed )
Supplement: 41698_2024_610_MOESM3_ESM.xlsx › Supplementary_Data_2
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
38496837 (PubMed )
Supplement: mmc1.xlsx › Sheet1
p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
Sakamoto I et al.
The American Journal of Surgical Pathology, 2023
TP53 germline pathogenic variants in modern humans were likely originated during recent human history.
Kou SH et al.
Nar Cancer, 2023
37304756 (PubMed )
Supplement: zcad025_supplemental_files.zip › Supplementary_Table_2.xlsx › PVs
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview.
Özgü E et al.
Jco Precision Oncology, 2023
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.
Isobe T et al.
Nature Communications, 2022
36042201 (PubMed )
Supplement: 41467_2022_32266_MOESM12_ESM.xlsx › Data9
Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma.
Chung C et al.
Oncology (williston Park, N.y.), 2021
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF et al.
Jama Oncology, 2021
33630025 (PubMed )
Supplement: jamaoncol-e207987-s004.xlsx › Table
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis.
Hoefflin R et al.
Cancers, 2021
33800365 (PubMed )
Supplement: cancers-13-01151-s001.zip › Supplementary_Data_2.xlsx › Cosmic_Annotated_Mutations
A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.
Ceder S et al.
Embo Molecular Medicine, 2021
33314700 (PubMed )
Supplement: EMMM-13-e10852-s001.pdf
Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ et al.
Cell Research, 2021
32719455 (PubMed )
Supplement: 41422_2020_375_MOESM12_ESM.xlsx › Sheet1
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Sivapiragasam A et al.
Cancer Medicine, 2021
33314633 (PubMed )
Supplement: CAM4-10-53-s003.xlsx › Sheet1
Identification of relevant genetic alterations in cancer using topological data analysis.
Rabadán R et al.
Nature Communications, 2020
32732999 (PubMed )
Supplement: 41467_2020_17659_MOESM3_ESM.xls › TableS1
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Wang Y et al.
Scientific Reports, 2020
Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents.
Rachiglio AM et al.
Cancers, 2019
31226844 (PubMed )
Supplement: cancers-11-00859-s001.pdf
Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
Tong L et al.
Theranostics, 2019
31534501 (PubMed )
Supplement: thnov09p5532s1.pdf
Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO et al.
Nature Genetics, 2018
30224644 (PubMed )
Supplement: NIHMS1501645-supplement-3.xlsx › Sheet1
Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA.
Clark TA et al.
The Journal of Molecular Diagnostics : Jmd, 2018
29936259 (PubMed )
Supplement: mmc12.xlsx › Table_S12
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
28775315 (PubMed )
Supplement: 41467_2017_289_MOESM7_ESM.xlsx › mutation_data
Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
Cho SY et al.
Gastroenterology, 2017
28522256 (PubMed )
Supplement: NIHMS1058936-supplement-Table_S3.xlsx › VCF
The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.
Coaxum SD et al.
Oncotarget, 2017
Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.
Yaeger R et al.
Gastroenterology, 2016
Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.
Xiu J et al.
Oncotarget, 2016
26933808 (PubMed )
Supplement: oncotarget-07-21556-s001.pdf
Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors.
Sonkin D
Elife, 2015
Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.
Grünewald I et al.
Oncotarget, 2015
Mutational landscape and significance across 12 major cancer types.
Kandoth C et al.
Nature, 2013
24132290 (PubMed )
Supplement: 41586_2013_BFnature12634_MOESM82_ESM.zip › nature12634-s1 › Supplementary_Table_5.xlsx › S_Table_5
TP53 lacks tetramerization and N-terminal domains due to novel inactivating mutations detected in leukemia patients.
Hameed Y et al.
Journal of Cancer Research and Therapeutics, 0
Select a paper to view details